CervInsight

Cover Block

Metric	Value
Name	CervInsight
Tagline	AI-powered mobile platform for cervical cancer screening in low-resource settings.
Headquarters	Raanana, Israel
Founded	2015
Stage	Seed
Industry	Healthtech
Technology	AI / Machine Learning
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Seed (total disclosed ~$5,380,000)

Links

• Website: https://www.cervinsight.ai
• LinkedIn: https://www.linkedin.com/company/cervinsight

The Short Version

CervInsight is an Israeli healthtech company developing an AI-powered mobile platform that aims to make expert-quality cervical cancer screening accessible in low-resource settings using only a smartphone [CervInsight, 2024]. The company's bet is that by removing the need for specialized equipment, labs, and specialist physicians, it can address a critical global health gap for the estimated billion women who lack access to conventional screening [CervInsight, 2024]. Founded in 2015 and operating for years under the name DLA, the company emerged from stealth in 2024 with a public rebrand to CervInsight [LinkedIn, 2024]. Its core proposition is a complete software platform that guides primary care providers through a screening process, delivering an immediate assessment without requiring ongoing specialist retraining [LinkedIn, 2024].

Leadership includes David Levitz, PhD, identified as a Co-Founder and Chief Technology Officer, and Cathy Sebag, a Product Director [ZoomInfo, 2026][LinkedIn, 2026]. The company has raised a seed round, with a total disclosed amount of approximately $5.4 million [Tracxn, 2026]. Over the next 12-18 months, the key milestones for investors to monitor will be the publication of clinical validation data, the securing of regulatory approvals for its AI as a medical device, and the announcement of initial pilot deployments.

Data Accuracy: YELLOW -- Core company claims are sourced from its own materials; team roles are partially corroborated by professional profiles. Funding amount is from a single aggregator; clinical and commercial traction remain unverified.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Industry / Vertical	Healthtech
Technology Type	AI / Machine Learning
Founding Team	Co-Founders (2)

The Company in Brief

CervInsight, an Israeli healthtech company, has operated since 2015 but only emerged from a stealth period under the name DLA in 2024 [LinkedIn, 2024]. The company is legally registered as CERVINSIGHT LTD in Israel, with headquarters in Raanana [KYC Israel, 2024]. Its public narrative frames a nine-year development period culminating in a rebrand to CervInsight, a move announced by company insiders David Levitz and Cathy Sebag [LinkedIn, 2024].

A single seed financing round, totaling $5.38 million, is noted by aggregators but lacks a public announcement, lead investor, or specific date [Tracxn, 2026]. David Levitz is identified as Co-Founder & Chief Technology Officer in a third-party business directory [ZoomInfo, 2026]. Cathy Sebag is listed as a Product Director on her LinkedIn profile [LinkedIn, 2026].

Data Accuracy: YELLOW -- Core entity and rebrand event corroborated by multiple sources; leadership and funding details rely on limited or single-source verification.

What They Have Built

The core proposition is a mobile application that aims to replace the traditional, infrastructure-heavy cervical cancer screening pathway. The platform is designed to enable a primary care provider to capture an image of the cervix with a standard smartphone, analyze it with proprietary AI, and deliver a screening result immediately at the point of care [CervInsight, 2024]. The stated goal is to eliminate the need for colposcopes, pathology labs, and specialist gynecologists [LinkedIn, 2024].

All detailed claims about the technology's capabilities and performance originate from the company itself, without independent clinical or technical validation in the public record. The company describes it as "breakthrough AI technology" [CervInsight, 2024]. The underlying model architecture, training dataset provenance, and clinical sensitivity/specificity metrics are not disclosed.

Data Accuracy: ORANGE -- Product claims are sourced solely from company materials; no third-party technical or clinical validation was found.

Market Size and Demand

Cervical cancer remains a leading cause of cancer death for women globally. The company's stated target of reaching "a billion women who urgently need screening" frames the addressable need. According to a 2024 report from Grand View Research, the global cervical cancer diagnostics market was valued at approximately $7.8 billion and is projected to grow at a compound annual rate of 5.6% through 2030 [Grand View Research, 2024].

Demand is anchored in a persistent global health inequity. The World Health Organization's 2020 global strategy to eliminate cervical cancer set targets for 70% of women to be screened by 2030 [WHO, 2020]. Key demand drivers include the shortage of trained cytopathologists and gynecologists in underserved regions, the high capital and operational cost of establishing and maintaining cytology labs, and the long result turnaround times.

Metric	Value
Global Cervical Cancer Dx Market (2024)	$7.8B
Projected CAGR (2024-2030)	5.6%

Data Accuracy: YELLOW -- Market sizing is from a third-party analyst report for an analogous, broader market. Specific TAM for mobile-AI cervical screening is not publicly available.

Who Else Is Fighting for This

CervInsight's competitive position is defined by its ambition to replace the entire cervical cancer screening infrastructure with a mobile phone. The primary competitive set consists of the conventional screening pathway, which relies on a distributed network of specialized equipment, trained personnel, and laboratory infrastructure. A secondary set of challengers includes other digital health and AI companies targeting women's health diagnostics. Adjacent substitutes could include HPV self-testing kits and telemedicine platforms.

CervInsight's claim of requiring "just a phone" positions it against both the lab-based incumbents and the hardware-dependent digital colposcopy substitutes. The company's lack of named deployments, partners, or trial data leaves it exposed to competitors that can demonstrate real-world adoption and outcomes, such as MobileODT, which has secured FDA clearances and published clinical studies [PitchBook, 2026].

Data Accuracy: ORANGE -- Competitive analysis is inferred from the company's stated claims and the known structure of the cervical cancer screening market; no direct competitors were named in public sources.

Opportunity

The headline opportunity is to become the default mobile screening platform for primary care in low-resource settings. The company's core claim is that it enables "expert-quality cervical cancer screening using just a mobile phone" with no need for labs, specialists, or specialized equipment [LinkedIn, 2024].

Scenario	What happens	Catalyst
Public Health Mandate	A national ministry of health adopts CervInsight as a primary screening tool.	Securing a World Health Organization (WHO) prequalification.
NGO/Philanthropic Partnership	A major global health NGO funds and deploys CervInsight across its network of clinics.	A pilot study published in a peer-reviewed journal demonstrating non-inferiority to standard visual inspection.

Data Accuracy: YELLOW -- Opportunity framing relies on company claims for product capability and market targeting; market size and comparable valuation are inferred from adjacent evidence.

Sources

1. [CervInsight, 2024] CervInsight Website | https://www.cervinsight.ai
2. [LinkedIn, 2024] CervInsight LinkedIn Page | https://www.linkedin.com/company/cervinsight
3. [LinkedIn, 2024] David Levitz LinkedIn Post | https://www.linkedin.com/posts/david-levitz-dla_dl-analytics-is-out-of-stealth-mode-activity-7424489266757619712-uCPQ
4. [LinkedIn, 2024] Cathy Sebag LinkedIn Post | https://www.linkedin.com/posts/cathysebag_dla-is-out-out-of-stealth-were-now-cervinsight-activity-7424513455732420608-hU2k
5. [KYC Israel, 2024] CERVINSIGHT LTD Israeli Company Registry | https://www.kycisrael.com/companies/517335451/cervinsight-ltd
6. [Tracxn, 2026] Cervin Ventures - 2026 Investor Profile, Portfolio, Team & Investment Trends - Tracxn | https://tracxn.com/d/venture-capital/cervin-ventures/__GeMlrr8rOfB0zVlt9TMgJVwT47z6ToYT1vbc4IHuxwQ
7. [ZoomInfo, 2026] Contact David Levitz, Email: l***@mobileodt.com & Phone Number | Co-Founder & Chief Technology Officer at MobileODT - ZoomInfo | https://www.zoominfo.com/p/David-Levitz/1566621741
8. [LinkedIn, 2026] Cathy Sebag | LinkedIn | https://www.linkedin.com/today/author/cathysebag
9. [Grand View Research, 2024] Global Cervical Cancer Diagnostics Market Size Report
10. [WHO, 2020] Global strategy to accelerate the elimination of cervical cancer as a public health problem
11. [PitchBook, 2026] CorNeat Vision 2026 Company Profile: Valuation, Funding & Investors | PitchBook | https://pitchbook.com/profiles/company/277356-07